Aligos Therapeutics Director Heather Preston Receives Stock Options

Heather Preston, a director of Aligos Therapeutics, Inc., received a stock option grant for 5,860 shares of common stock on June 25, 2026. The options have an exercise price of $5.50 per share and expire on June 25, 2036. The options will vest and become exercisable as to 100% of the shares on the earlier of the first anniversary of the grant date or immediately prior to the company's 2027 annual stockholders meeting, subject to continuous service through the vesting date. This Form 4 filing reports the acquisition of derivative securities by a company director, which is a standard disclosure for equity compensation awards to corporate insiders. The transaction represents equity-based compensation for board service.